Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

TriSalus Life Sciences (TLSI) Operating Expenses (2022 - 2026)

TriSalus Life Sciences has reported Operating Expenses over the past 5 years, most recently at $8.7 million for Q1 2026.

  • For Q1 2026, Operating Expenses rose 4.84% year-over-year to $8.7 million; the TTM value through Mar 2026 reached $36.8 million, up 10.08%, while the annual FY2025 figure was $36.4 million, 2.16% up from the prior year.
  • Operating Expenses for Q1 2026 was $8.7 million at TriSalus Life Sciences, up from $6.7 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $18.5 million in Q3 2023 and troughed at $288273.0 in Q2 2022.
  • A 5-year average of $9.0 million and a median of $8.9 million in 2024 define the central range for Operating Expenses.
  • Biggest five-year swings in Operating Expenses: surged 3987.1% in 2023 and later plummeted 51.72% in 2024.
  • Year by year, Operating Expenses stood at $10.3 million in 2022, then soared by 33.49% to $13.8 million in 2023, then crashed by 44.75% to $7.6 million in 2024, then dropped by 11.48% to $6.7 million in 2025, then grew by 28.57% to $8.7 million in 2026.
  • Business Quant data shows Operating Expenses for TLSI at $8.7 million in Q1 2026, $6.7 million in Q4 2025, and $11.8 million in Q3 2025.